Recombinant Proteins

p53
LBP
CEA
HLA
TCL
TTC
NPM
MAF
Bax
BID

BAG1 Human

BCL2-Associated Athanogene 1 Human Recombinant

Recombinant Human BAG1, produced in E. coli, is a single, non-glycosylated polypeptide chain consisting of 230 amino acids (1-230 a.a.). With a molecular weight of 25.9 kDa, the protein is purified using standard chromatographic techniques.
Shipped with Ice Packs
Cat. No.
BT23030
Source
Escherichia Coli.
Appearance
A clear, colorless solution that has been sterilized by filtration.

BAG2 Human

BCL2-Associated Athanogene 2 Human Recombinant

Recombinant Human BAG2, fused with a 20 amino acid His tag at its N-terminus, is produced in E. coli. This results in a single, non-glycosylated polypeptide chain comprising 231 amino acids (specifically, amino acids 1-211) and possessing a molecular weight of 25.9 kDa. Purification of the BAG2 protein is achieved through proprietary chromatographic methods.
Shipped with Ice Packs
Cat. No.
BT23111
Source
Escherichia Coli.
Appearance
A clear, colorless solution that has been sterilized by filtration.

BAG3 Human

BCL2-Associated Athanogene 3 Human Recombinant

This product consists of recombinant human BAG3 protein produced in E. coli. It is a single, non-glycosylated polypeptide chain encompassing 595 amino acids (residues 1-575) with a molecular weight of 63.7 kDa. A 20 amino acid His-tag is fused to the N-terminus of the protein. Purification is achieved through standard chromatographic techniques.
Shipped with Ice Packs
Cat. No.
BT23162
Source
Escherichia Coli.
Appearance
Clear, colorless solution that has been sterilized by filtration.

Bcl 2 Human (minus BH4 domain)

B-Cell Leukemia/Lymphoma 2 Human Recombinant (-BH4)

Bcl-2 Human Recombinant (minus BH4 domain) produced in E.Coli is a single, non-glycosylated polypeptide chain containing 197 amino acids (1-9 and 31-218) and having a molecular mass of 21.8kDa.Bcl-2 is fused to a 6 amino acid His-tag at C-Terminus & purified by proprietary chromatographic techniques.
Shipped with Ice Packs
Cat. No.
BT23570
Source
Escherichia Coli.
Appearance
Sterile Filtered Lyophilized (freeze-dried) powder.

Bcl 2 Human (minus NWGR domain)

B-Cell Leukemia/Lymphoma 2 Human Recombinant (–NWGR)

This product consists of a recombinant human Bcl-2 protein with a deleted NWGR domain (amino acid residues 143-146). It is produced in E. coli bacteria and purified to a single, non-glycosylated polypeptide chain comprising 214 amino acids (residues 1-142 and 147-218). The protein is engineered with a His-Tag for purification purposes and purified using proprietary chromatographic methods.
Shipped with Ice Packs
Cat. No.
BT23646
Source
Escherichia Coli.
Appearance
The product appears as a sterile, filtered white powder that has been freeze-dried (lyophilized).

Bcl XL Human

B-Cell Lymphoma Extra Large Human Recombinant

Recombinant human Bcl-XL, produced in E. coli, is a single, non-glycosylated polypeptide chain comprising amino acids 1 to 210. The purification of Bcl-XL is achieved through proprietary chromatographic techniques.
Shipped with Ice Packs
Cat. No.
BT23725
Source
Escherichia Coli.
Appearance
White lyophilized (freeze-dried) powder, sterile filtered.

Bcl XL Human, GST

B-Cell Lymphoma Extra Large Human Recombinant, GST

Recombinant human Bcl-XL, produced in E. coli, is a single, non-glycosylated polypeptide chain comprising amino acids 1-210. It is expressed as a GST-tagged fusion protein and purified using proprietary chromatographic techniques.
Shipped with Ice Packs
Cat. No.
BT23827
Source
Escherichia Coli.
Appearance
Sterile Filtered White lyophilized powder.

BCL2 Human, His

B-Cell Lymphoma Protein 2 Alpha Human Recombinant, His Tag

Recombinant BCL2 Human, manufactured in E. coli, is a single, non-glycosylated polypeptide chain. This protein consists of amino acids 1-211, resulting in a molecular weight of 25.4 kDa. A 20 a.a. His-Tag is fused to the N-terminus of the BCL2 protein. Purification is achieved using proprietary chromatographic methods.
Shipped with Ice Packs
Cat. No.
BT24291
Source
Escherichia Coli.
Appearance
A clear, colorless solution that has been sterilized by filtration.

BCL2A1 Human

BCL2-Related Protein A1 Human Recombinant

Recombinant human BCL2A1, produced in E. coli, is a single polypeptide chain consisting of 176 amino acids (residues 1-152). It has a molecular weight of 20.2 kDa. The protein includes a 24 amino acid His-tag fused to its N-terminus and is purified using standard chromatography techniques.
Shipped with Ice Packs
Cat. No.
BT24366
Source
E.coli.
Appearance
The product is a clear, sterile solution without any color.

BCL2L1 Mouse

BCL2-Like 1 Recombinant Mouse

Recombinant BCL2L1 from mouse, produced in E. coli, is a single, non-glycosylated polypeptide chain comprising 232 amino acids (residues 1-209) with a molecular weight of 25.8 kDa. The protein consists of a 23-amino acid His-tag fused to the N-terminus of BCL2L1. Purification is achieved using proprietary chromatographic techniques.
Shipped with Ice Packs
Cat. No.
BT24417
Source
Escherichia Coli.
Appearance
Clear, colorless, and sterile-filtered solution.
Definition and Classification

B cell lymphoma is a type of non-Hodgkin lymphoma that originates in B cells, which are a type of white blood cell responsible for producing antibodies. It is the most common type of lymphoma, accounting for about 85% of all lymphomas in the United States . B cell lymphomas are classified into various subtypes based on their histological and genetic characteristics. The World Health Organization (WHO) and the International Consensus Classification (ICC) provide the most widely used classification systems. These classifications include subtypes such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, and marginal zone lymphoma .

Biological Properties

B cell lymphomas exhibit diverse biological properties, including distinct expression patterns and tissue distribution. For instance, DLBCL is characterized by its heterogeneity in gene expression and clinical behavior . B cell lymphomas can arise in various tissues, including lymph nodes, spleen, bone marrow, and extranodal sites such as the stomach, lungs, and skin . The microenvironment of B cell lymphomas plays a crucial role in their biology, influencing tumor growth and response to therapy .

Biological Functions

B cells are essential components of the adaptive immune system. They produce antibodies that neutralize pathogens and facilitate their clearance by other immune cells . In the context of B cell lymphoma, malignant B cells retain some of these functions but also acquire properties that promote tumor growth and survival. For example, they can evade immune surveillance and create an immunosuppressive microenvironment . B cell lymphomas can also disrupt normal immune responses, leading to immunodeficiency and increased susceptibility to infections .

Modes of Action

The pathogenesis of B cell lymphoma involves complex interactions with other molecules and cells. Key binding partners include antigens recognized by the B cell receptor (BCR) and molecules involved in signaling pathways such as CD20 and CD19 . Downstream signaling cascades activated by these interactions include the PI3K/AKT/mTOR and NF-κB pathways, which promote cell survival, proliferation, and resistance to apoptosis . Therapeutic strategies often target these pathways to inhibit tumor growth and enhance immune responses .

Regulatory Mechanisms

The expression and activity of B cell lymphoma-related genes are tightly regulated at multiple levels. Transcriptional regulation involves factors such as MYC, BCL2, and BCL6, which are frequently dysregulated in B cell lymphomas . Post-translational modifications, including phosphorylation and ubiquitination, further modulate the activity of key signaling proteins . Epigenetic mechanisms, such as DNA methylation and histone modifications, also play a role in regulating gene expression and maintaining the malignant phenotype .

Applications

B cell lymphomas have significant implications in biomedical research, diagnostics, and therapeutics. In research, they serve as models for studying the mechanisms of lymphomagenesis and immune evasion . Diagnostic tools include immunohistochemistry, flow cytometry, and molecular techniques to identify specific markers and genetic abnormalities . Therapeutic strategies encompass conventional chemotherapy, targeted therapies such as monoclonal antibodies (e.g., rituximab), and advanced approaches like chimeric antigen receptor (CAR) T-cell therapy .

Role in the Life Cycle

B cell lymphomas can arise at any stage of life, from childhood to old age. The risk of developing B cell lymphoma increases with age, and certain genetic and environmental factors contribute to its pathogenesis . During the life cycle, B cell lymphomas can undergo clonal evolution, leading to changes in their biological behavior and response to treatment . Understanding the life cycle of B cell lymphomas is crucial for developing effective therapeutic strategies and improving patient outcomes .

© Copyright 2024 Thebiotek. All Rights Reserved.